01
Science first
We look for differentiated therapeutic hypotheses supported by strong biological and translational evidence.
Early-stage therapeutics investors
From breakthrough science to clinical impact.
We invest in early-stage therapeutics companies and build new ones around exceptional science, combining scientific judgment, capital and hands-on support to advance promising programmes towards clinical validation.
Our investment approach
Great biotech starts with better questions.
We invest before the path is obvious. Our edge is the ability to identify differentiated biology, assess development paths and support exceptional teams from company formation through early clinical development.
02
Invest and create
We invest in compelling existing companies and also work with scientific founders to build new biotech companies from the ground up.
03
Clinical value
We focus our capital and support on milestones that reduce development risk and establish clinical relevance.
04
Global perspective
We help companies access international talent, specialist investors, clinical networks and pharmaceutical partners — wherever the science originates.
Our investment model
Two routes to investment. One rigorous approach.
Some investments begin with a scientific discovery and a founder. Others begin with an established company, an experienced team and a defined development plan. In both cases, we invest capital and contribute scientific judgment, governance support and industry connectivity.
01
Discover
We source opportunities through academic institutions, entrepreneurs, the international scientific community and AI-enabled scouting.
02
Assess
We evaluate the biology, translational evidence, intellectual property, product profile and development path.
Company creation
Build a new company
When an opportunity originates from academic science, we may help establish the company, shape its strategy and recruit its initial leadership.
From discovery to company
Direct investment
Back an existing company
When the company and team are already in place, we invest as a specialist venture capital firm and support the next phase of development.
Capital and active support
04
Support
We work alongside founders and management teams on strategy, governance, financing, organisational development and business development.
05
Advance
We focus on scientific and clinical milestones that validate the programme and open new strategic opportunities.
What we look for
Focused on the inflection points that matter.
We invest from company formation through early clinical development, focusing on therapeutic programmes where specialist capital and active support can unlock a meaningful inflection point.
01
Therapeutics
We invest exclusively in companies developing new medicines.
02
Early stage
We invest from company formation and preclinical development through the early clinical stages.
03
Evidence-led
We look for differentiated biology, compelling experimental evidence and a credible translational path.
04
Clinically meaningful
We back programmes addressing significant unmet medical needs, with the potential to deliver meaningful benefit for patients.
We are modality-agnostic and invest across therapeutic areas where the scientific rationale and development opportunity are compelling.
Selected portfolio
Companies built and backed around meaningful science.
Resalis Therapeutics
Advancing first-in-class non-coding RNA medicines for obesity and metabolic disease.
Explore the company ↗IAMA Therapeutics
Restoring neuronal chloride homeostasis in serious central nervous system disorders.
Explore the company ↗Kither Biotech
Developing new therapies for severe respiratory diseases.
Explore the company ↗ALKemist Bio
Developing next-generation CAR-T and TCR-T cell therapies for solid tumours.
Explore the company ↗Start a conversation